Trailing-twelve-month (TTM) revenue is $3.15 Billion with a year-over-year growth of +2.49%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $799,500,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-29 |
| Q4 FY2025Period ended 2025-12-31 | $790,200,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-25 |
| Q1 FY2026Period ended 2026-03-31 | $781,500,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $783,300,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $3,154,500,000 |
Current P/S: $21,100,679,037 market capitalization ÷ $3,154,500,000 TTM revenue = 6.69x.
Market capitalization source: FMP quote. Quote observed 2026-09-11T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $783.30M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-12T00:16:11.359Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Adcirca | $67M | $56M | N/A | $29M | $24M | $30M |
| Orenitram | $293M | $306M | $325M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| European Union And Others | $71M | N/A | N/A | N/A | N/A | N/A |
| Non-US | N/A | $121M |
$3.15B
$3.15 Billion
+2.49%
vs. $3.08B a year ago (TTM)
+14.68%
5 Year compound annual growth rate
1 Year
+2.49%
3 Year
+14.32%
5 Year
+14.68%
10 Year
+7.21%
15 Year
+10.70%
20 Year
+17.02%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $3.18B | +$305.30M | +10.61% |
| 2024 | $2.88B | +$549.90M | +23.63% |
| 2023 | $2.33B | +$391.20M | +20.20% |
| 2022 | $1.94B | +$250.80M | +14.88% |
| 2021 | $1.69B | +$202.20M | +13.63% |
| 2020 |
TTM Growth
+2.49%
3-Year CAGR
+14.32%
5-Year CAGR
+14.68%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-12T00:16:11.359Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $434M |
| $497M |
| Product and Service, Other | N/A | N/A | $14M | $12M | $22M | $24M |
|---|
| Remodulin | $517M | $514M | $500M | $495M | $538M | $527M |
|---|
| Tyvaso | N/A | $608M | $873M | $1.2B | $1.6B | $1.9B |
|---|
| Unituxin | $123M | $202M | $183M | $199M | $239M | $227M |
|---|
| $125M |
| $138M |
| $146M |
| UNITED STATES | $1.4B | $1.6B | $1.8B | $2.2B | $2.7B | $3.0B |
|---|
| $1.48B |
| +$34.50M |
| +2.38% |
| 2019 | $1.45B | ($179.00M) | (11.00%) |
| 2018 | $1.63B | ($97.50M) | (5.65%) |
| 2017 | $1.73B | +$126.50M | +7.91% |
| 2016 | $1.60B | +$133.04M | +9.08% |
